ASLAN Pharmaceuticals Enters Into a Strategic Licensing Deal With Zenyaku Kogyo for the Development and Commercialization of Eblasakimab in Japan
ASLAN will receive up to $15 million in upfront and near-term payments and up to an additional $123.5 million based...